Nicotinamide Phosphoribosyltransferase – Pipeline Review, H2 2019

“Global Markets Direct’s, ‘Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12)- Pipeline Review, H2 2019’, provides in depth analysis on Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12) targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12) targeted therapeutics development and features dormant and discontinued projects. The report analyses the pipeline products from therapy areas Oncology, Central Nervous System, Cardiovascular, Immunology and Respiratory under development targeting Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12).

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.”

Scope


– The report provides a snapshot of the global therapeutic landscape for Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12)

– The report reviews Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved in Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12) targeted therapeutics and enlists all their major and minor projects

– The report assesses Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news and deals related to Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12) targeted therapeutics”

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

“AbbVie Inc

Angelini Group

Aqualung Therapeutics Corp

Aurigene Discovery Technologies Ltd

Calico LLC

Eli Lilly and Co

Genentech Inc

Karyopharm Therapeutics Inc

OncoTartis Inc

Tianjin Hemay Pharmaceutical Co Ltd”

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC

2.4.2.12) Overview

Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC

2.4.2.12) Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC

2.4.2.12) Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC

2.4.2.12) Companies Involved in Therapeutics Development

AbbVie Inc

Angelini Group

Aurigene Discovery Technologies Ltd

Calico LLC

Eli Lilly and Co

Genentech Inc

Karyopharm Therapeutics Inc

OncoTartis Inc

Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC

2.4.2.12) Drug Profiles

AU-4869 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Drugs to Inhibit NAMPT for Inflammation and Pain Drug Profile

Product Description

Mechanism Of Action

R&D Progress

enamptcumab Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GNE-617 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KPT-9274 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LSN-3154567 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

OT-82 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

P7-C3A20 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Activate NAMPT for Neurological Disorders Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit NAMPT for Oncology Drug Profile

Product Description

Mechanism Of Action

R&D Progress

STF-118804 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC

2.4.2.12) Dormant Products

Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC

2.4.2.12) Discontinued Products

Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC

2.4.2.12) Product Development Milestones

Featured News & Press Releases

Mar 19, 2018: Karyopharm to Present Preclinical Data on KPT-9274 at the American Association for Cancer Research 2018 Annual Meeting

Sep 08, 2017: Karyopharm Announces Presentation of KPT-9274 Clinical Data at European Society of Medical Oncology 2017 Annual Meeting

Aug 30, 2017: Karyopharm Announces the Presentation of KPT-9274 Clinical Data at the European Society of Medical Oncology 2017 Annual Meeting

Aug 01, 2016: Pharmatek, a San Diego based contract development & manufacturing company, started the development of OT-82 dosage form for human clinical studies

Jun 27, 2016: OncoTartis: Initiated OT-82 GLP Toxicology and Safety Pharmacology studies

Jun 22, 2016: Karyopharm Initiates Phase 1 Clinical Trial with KPT-9274

Mar 16, 2016: Karyopharm to Present Data on Oncology drug KPT-9274 at the 2016 American Association for Cancer Research Annual Meeting

Mar 15, 2016: OncoTartis Provides Update on OT-82

Apr 18, 2015: Aurigene to Present its NAMPT Inhibitors Programs at AACR 2015

Mar 30, 2015: Oncotartis in collaboration with scientists from the Children’s Cancer Institute of Australia for Medical Research initiated testing of OT-82

Oct 30, 2014: OncoTartis Provides Update on Toxicology study of OT-82

May 16, 2014: Nanosyn, a Santa Clara, CA based chemistry CRO, completed process development for scaling up and manufacturing OT-82 drug candidate on a kilo scale

Nov 01, 2013: Novel drug discovery method designed by Stanford scientists

Apr 02, 2013: Aurigene To Present Poster On NAMPT Inhibitor Program At AACR 2013

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

“List of Tables

Number of Products under Development by Stage of Development, H2 2019

Number of Products under Development by Therapy Areas, H2 2019

Number of Products under Development by Indications, H2 2019

Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019

Number of Products under Development by Companies, H2 2019

Products under Development by Companies, H2 2019

Products under Development by Companies, H2 2019 (Contd..1), H2 2019

Products under Development by Companies, H2 2019 (Contd..2), H2 2019

Number of Products under Investigation by Universities/Institutes, H2 2019

Products under Investigation by Universities/Institutes, H2 2019

Number of Products by Stage and Mechanism of Actions, H2 2019

Number of Products by Stage and Route of Administration, H2 2019

Number of Products by Stage and Molecule Type, H2 2019

Pipeline by AbbVie Inc, H2 2019

Pipeline by Angelini Group, H2 2019

Pipeline by Aqualung Therapeutics Corp, H2 2019

Pipeline by Aurigene Discovery Technologies Ltd, H2 2019

Pipeline by Calico LLC, H2 2019

Pipeline by Eli Lilly and Co, H2 2019

Pipeline by Genentech Inc, H2 2019

Pipeline by Karyopharm Therapeutics Inc, H2 2019

Pipeline by OncoTartis Inc, H2 2019

Pipeline by Tianjin Hemay Pharmaceutical Co Ltd, H2 2019

Dormant Projects, H2 2019

Discontinued Products, H2 2019”

List of Figures

“List of Figures

Number of Products under Development by Stage of Development, H2 2019

Number of Products under Development by Therapy Areas, H2 2019

Number of Products under Development by Top 10 Indications, H2 2019

Number of Products by Mechanism of Actions, H2 2019

Number of Products by Stage and Mechanism of Actions, H2 2019

Number of Products by Routes of Administration, H2 2019

Number of Products by Stage and Routes of Administration, H2 2019

Number of Products by Molecule Types, H2 2019

Number of Products by Stage and Molecule Types, H2 2019”

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports